- Report
- May 2026
- 250 Pages
Global
From €3973EUR$4,490USD£3,404GBP
- Report
- April 2026
- 160 Pages
Global
From €2938EUR$3,320USD£2,517GBP
€3672EUR$4,150USD£3,147GBP
- Report
- July 2026
- 218 Pages
Global
From €4246EUR$4,799USD£3,639GBP
- Report
- August 2026
- 182 Pages
Global
From €3137EUR$3,545USD£2,688GBP
€3485EUR$3,939USD£2,987GBP
- Report
- January 2026
- 198 Pages
Global
From €3137EUR$3,545USD£2,688GBP
€3485EUR$3,939USD£2,987GBP
- Report
- February 2026
- 250 Pages
Global
From €3973EUR$4,490USD£3,404GBP
- Report
- August 2026
- 82 Pages
Global
From €5176EUR$5,850USD£4,436GBP
- Report
- August 2026
- 250 Pages
Global
From €3973EUR$4,490USD£3,404GBP
- Report
- February 2026
- 250 Pages
Global
From €3973EUR$4,490USD£3,404GBP
- Report
- February 2026
- 250 Pages
Global
From €3973EUR$4,490USD£3,404GBP
- Report
- February 2026
- 250 Pages
Global
From €3973EUR$4,490USD£3,404GBP
- Report
- May 2026
- 30 Pages
Global
From €2433EUR$2,750USD£2,085GBP
- Clinical Trials
- April 2026
- 450 Pages
Global
From €4424EUR$5,000USD£3,791GBP
- Report
- December 2025
- 200 Pages
Global
From €7034EUR$7,950USD£6,028GBP
- Report
- July 2026
- 160 Pages
Global
From €4203EUR$4,750USD£3,602GBP
- Report
- July 2026
- 100 Pages
Global
From €4203EUR$4,750USD£3,602GBP
- Report
- July 2026
- 110 Pages
Global
From €4203EUR$4,750USD£3,602GBP
- Report
- July 2026
- 70 Pages
Global
From €4203EUR$4,750USD£3,602GBP
- Report
- April 2026
- 100 Pages
Global
From €4203EUR$4,750USD£3,602GBP
- Report
- July 2026
- 160 Pages
Global
From €3672EUR$4,150USD£3,147GBP

The Incretin market is a subset of the larger Diabetes Drugs market. Incretin drugs are a class of medications used to treat type 2 diabetes. They work by stimulating the release of insulin from the pancreas in response to meals, and by reducing the production of glucose by the liver. Incretin drugs are typically taken orally, and are often used in combination with other diabetes medications.
The Incretin market is highly competitive, with a number of major pharmaceutical companies offering products. These companies are investing heavily in research and development to create new and improved treatments.
Some of the major companies in the Incretin market include Novo Nordisk, Eli Lilly, Merck, AstraZeneca, and Boehringer Ingelheim. Show Less Read more